March 3, 2025 - 09:48
Azzur Group, a prominent service provider for FDA-regulated pharmaceutical and biotech firms, has confirmed that it has reached an agreement to sell its consulting business for $56 million to ELIQUENT Life Sciences. This strategic move is aimed at enhancing Azzur's focus on its core competencies while allowing ELIQUENT to expand its service offerings in the life sciences sector.
The transaction is expected to provide Azzur with additional resources to invest in its primary operations, which include providing compliance, validation, and quality assurance services to its clients. The sale is anticipated to close in the upcoming weeks, pending customary regulatory approvals.
Azzur Group's leadership expressed confidence that this divestiture will enable the company to streamline its operations and better serve its clients in the pharmaceutical and biotechnology industries. Meanwhile, ELIQUENT Life Sciences is poised to leverage the acquired consulting expertise to bolster its position in the market, further enhancing its commitment to delivering innovative solutions in life sciences.
